There is, however, a synthetic analog of TH4 called TB-500, which has been investigated as a treatment for neurodegenerative conditions like multiple sclerosis, but its use is still largely experimental [4]
At its July 23-24, 2026 meeting, the FDAs Pharmacy Compounding Advisory Committee reviews seven peptides for 503A eligibility: on July 23, BPC-157, KPV, TB-500, and MOTS-C
We can introduce you to professional, English-speaking physicians
Many of the FDA advisers and internal staff who oversaw those decisions no longer work for the agency
Across several votes, the panelists voted 8-6, with one abstention, in favor of putting the peptides on the FDA's list of substances considered safe for pharmacy compounding
Click Here Now to see their page on Epitalon